News
Patients gain access to innovative new procedure for treating knee osteoarthritis as HCA UK partners with Contura Orthopaedics
Date: 20 October 2022
Contura announces new CEO to accelerate future growth
Date: 16 November 2021
Contura sells Bulkamid® to Axonics Modulation Technologies, Inc
Date: 26 February 2021
Bulkamid: one year anniversary of FDA approval in the United States
Date: 28 January 2021
Completion of prospective open label clinical study of Arthrosamid® for knee osteoarthritis
Date: 9 October 2020
Completion of recruitment for a multi-center, randomized, controlled clinical study of Arthrosamid® for knee osteoarthritis.
Date: 20 May 2020
Approval of Arthrosamid®
for the treatment of knee osteoarthritis
for the treatment of knee osteoarthritis
Date: 15 April 2020
Contura expands its commercial efforts to the US
and appoints new US Leadership Team
and appoints new US Leadership Team
Date: 10 February 2020
FDA approves Bulkamid® in the United States and
is now set for launch in Quarter 1 2020
is now set for launch in Quarter 1 2020
Date: 31 January 2020
Results of Randomised Controlled Trial of Bulkamid® versus Tension-free
Vaginal Tape Published
Vaginal Tape Published
Date: 1 January 2020
Urethral bulking agents to be considered as two distinct
classes: particulate and non-particulate
classes: particulate and non-particulate
Date: 1 December 2019
Observational multicentered study shows that two thirds of women with
stress urinary incontinence choose Bulkamid® when offered a choice
stress urinary incontinence choose Bulkamid® when offered a choice
Date: 1 December 2019
Completion of recruitment to a prospective, open-label
clinical investigation of Arthrosamid for knee osteoarthritis
clinical investigation of Arthrosamid for knee osteoarthritis
Date: 17 October 2019
Commencement of a multi-center, randomized, controlled
clinical study of Arthrosamid® for knee osteoarthritis
clinical study of Arthrosamid® for knee osteoarthritis
Date: 15 June 2019
Acquisition of Manufacturing Facility in Copenhagen, Denmark
Date: 25 May 2018
Searchlight Pharma Announces Launch of Bulkamid® for Treatment of
Female Stress Urinary Incontinence
Female Stress Urinary Incontinence
Date: 10 May 2018
Speciality European Pharma Limited to rebrand as Contura in order to
consolidate its corporate structure and drive growth
consolidate its corporate structure and drive growth
Date: 19 January 2018
Contura files Bulkamid PMA
Date: 30 July 2017
Speciality European Pharma sells Mitem to Substipharm Limited
Date: 27 April 2017
Speciality European Pharma signs clinical research agreement with Central
Manchester University Hospitals NHS Foundation Trust for the study of
Bulkamid as a first line treatment for stress urinary incontinence
Manchester University Hospitals NHS Foundation Trust for the study of
Bulkamid as a first line treatment for stress urinary incontinence
Date: 17 February 2017
Speciality European Pharma extends distribution agreement for Regurin XL
in the United Kingdom
in the United Kingdom
Date: 20 December 2016
MBO at SEP provides capital to accelerate growth and expansion
Date: 1 May 2016
Contura signs clinical research agreement to initiate a randomised controlled
trial of Bulkamid against Tension-free Vaginal Tape
trial of Bulkamid against Tension-free Vaginal Tape
Date: 2 September 2015
Speciality European Pharma licenses distribution rights for Cystistat in
Germany and France
Germany and France
Date: 1 July 2015
Contura sells veterinary rights to Antematter
Date: 30 December 2014
Contura terminates Bulkamid distribution rights with Ethicon
Date: 3 May 2013
Speciality European Pharma acquires Contura A/S
Date: 30 April 2013